<SEC-DOCUMENT>0001171843-19-007363.txt : 20191108
<SEC-HEADER>0001171843-19-007363.hdr.sgml : 20191108
<ACCEPTANCE-DATETIME>20191108090642
ACCESSION NUMBER:		0001171843-19-007363
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20191107
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE:		20191108
DATE AS OF CHANGE:		20191108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		191202328

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_110819.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><B>FORM 8-K</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><B>CURRENT REPORT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>PURSUANT TO SECTION 13 OR 15(d)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Date of Report (Date of earliest event reported): November 7, 2019</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 18pt; text-align: center; text-indent: 0.2in; margin: 0"><B>BioCryst Pharmaceuticals, Inc.</B></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: center"><FONT STYLE="font-weight: normal"><I>(Exact Name of Registrant as Specified
in Charter)</I></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center; font-weight: bold"><FONT STYLE="font-size: 10pt"><B>000-23186</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>62-1413174</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(State or Other Jurisdiction</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(Commission</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(IRS Employer</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>of Incorporation)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>File Number)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>4505 Emperor Blvd., Suite 200<BR>
Durham, North Carolina 27703</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Address of Principal Executive Offices)</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(919) 859-1302</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Registrant&rsquo;s telephone number, including area code)</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">________________________________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Former Name or Former Address, if Changed Since Last Report)</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2
below):</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-style: normal; font-weight: 400; text-decoration: initial; color: (error); text-transform: none">&#9744;</FONT></FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-style: normal; font-weight: 400; text-decoration: initial; color: (error); text-transform: none">&#9744;</FONT></FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-style: normal; font-weight: 400; text-decoration: initial; color: (error); text-transform: none">&#9744;</FONT></FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;210.14d-2(b))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-style: normal; font-weight: 400; text-decoration: initial; color: (error); text-transform: none">&#9744;</FONT></FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0 0 0 0.5in">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; border: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 21%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 55%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>BCRX</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nasdaq global select market</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &sect;240.12b-2).</P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: -0.5in; margin: 6pt 0 12pt 0.5in">Emerging growth company &#9744;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><FONT STYLE="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT>&#9744;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B>Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">On November 7, 2019, BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
and Thomas R. Staab, II, the Company&rsquo;s Senior Vice President and Chief Financial Officer, as well as the Company&rsquo;s
principal accounting officer, mutually agreed that Mr. Staab will step down from the Company effective February 29, 2020 for personal
reasons. Mr. Staab will continue in his role through February 2020, when the Company expects to release its year-end 2019 financial
results, and then will serve as an advisor to the Company through the middle of 2020 pursuant to the Consulting Agreement described
below in order to facilitate a smooth transition to his successor. Mr. Staab&rsquo;s resignation from the Company is not the result
of any disagreement with the Company on any matter relating to the Company&rsquo;s operations, policies or practices.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">In connection with his departure, Mr. Staab and the Company entered into
a Separation Agreement dated November&nbsp;7, 2019 (the &ldquo;Separation Agreement&rdquo;) providing for severance pay in the
amount of $647,750.21, which amount will be paid in installments to be completed no later than March 15, 2021. In addition, the
Separation Agreement provides that the Company will reimburse Mr. Staab for COBRA premiums that Mr. Staab actually pays to continue
his coverage under the Company&rsquo;s group health/dental plan for up to 18 months following his effective termination date.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><FONT STYLE="font-size: 10pt">In addition, on November 7, 2019, Mr. Staab
and the Company entered into a Consulting Agreement, which will be effective as of February 29, 2020, providing</FONT> that Mr.
Staab will serve as a consultant to the Company for a period of up to four months following his departure to assist with the transition
and with certain ongoing matters as requested by the Company from time to time. For his service to the Company as a consultant,
Mr. Staab will receive a consulting fee of $5,000 per month and an hourly rate of $295 per hour for services in excess of 17 hours
per month.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">The Company will engage in a search for a new Chief Financial Officer.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B>SIGNATURES</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.2in; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 55%; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: November 8, 2019</FONT></TD>
    <TD STYLE="width: 45%; text-align: left"><FONT STYLE="font-size: 10pt"><B>BioCryst Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">By: <U>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><U>&nbsp;&nbsp;&nbsp;/s/ Alane Barnes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 20pt"><FONT STYLE="font-size: 10pt">Alane Barnes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 20pt"><FONT STYLE="font-size: 10pt">Senior Vice President
and Chief Legal Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
